"Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of delivering improved outcomes to patients with significant unmet need," said Roy Baynes, M.D., Ph.D. Chief Medical Officer of Eikon. "Despite advancements in NSCLC, the current standard of care was established over a decade ago and does not deliver durable benefit for many patients. EIK1001 is designed to drive an enhanced immune response by stimulating both innate and adaptive immunity, improving antigen presentation in secondary lymphoid tissues and recruiting a broader répertoire of T-cells. We are grateful to the patients and investigators participating in this study who are vital partners as we work to develop therapies that may deliver more meaningful and sustained responses for people living with cancer."